Article
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Cell communication and signaling : CCS - 24 Feb 2016
Halbach Sebastian, Hu Zehan, Gretzmeier Christine, Ellermann Julia, Wöhrle Franziska U, Dengjel Jörn, Brummer Tilman
Abstract excerpt
BACKGROUND: Chronic myeloid leukemia (CML) is driven by the fusion kinase Bcr-Abl. Bcr-Abl tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), revolutionized CML therapy. Nevertheless, about 20 % of CMLs display primary or acquired TKI resistance. TKI resistance can be either caused by mutations within the Bcr-Abl kinase domain or by aberrant signaling by its effectors, e.g. Lyn or Gab2. Bcr-Abl...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.